Session 3 – Advances in Precision Medicine
Date: 25 July (Thursday) 09:00 – 12:00 Venue: 3F, Bldg. A, CTBC Financial Park, Ballroom A
CEO, Asia, Middle East & Africa (AMEA)
Guardant Health Pte Ltd
Simranjit Singh is the CEO of Guardant Health AMEA (GH AMEA), Inc., a joint venture between Guardant Health, Inc. & Softbank. He has more than 15 years of senior management experience in Asia Pacific working with biopharma, diagnostics and medical device companies. He leads GH AMEA which is a global leader in precision oncology. GH AMEA’s comprehensive genomic profiling (liquid biopsy) tests are available in 31 different markets across Asia, Middle East & Africa and it has 2 regional offices in Singapore & Tokyo.
Prior to Guardant Health, Simranjit was the Vice President of the Medical Devices and Diagnostics Division at IQVIA where he delivered exponential revenue growth by driving business transformation & growing the clinical research, consulting & regulatory business to advance market share in Asia Pacific.
Simranjit also served for 3 years as the Chairman for BioSingapore & played an integral role in developing the biomedical sector in Singapore. He currently sits on the National Healthcare Innovation Centre Oversight Committee under Ministry of Health of Singapore. Session Speech Title & Synopsis: Precision oncology – trends and future
Treatments for cancer have been advancing at an accelerated pace in recent years, offering notable improvements in clinical benefit. The realization that cancer is predominantly a deadly genetic disease is becoming more widely recognized & there is now much greater focus on comprehensive genomic profiling to move away from a traditional trial & error approach to treatment selection to one that would maximize the advantage of precision medicine by enabling the “Use of the right drug, for the right patient at the right time”